Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
Date:10/24/2009

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2009 financial results after the Nasdaq market closes on Wednesday, October 28, 2009. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, October 29, 2009 at 8:30 a.m. Eastern Daylight Time (5:30 a.m. Pacific Daylight Time).

Participants can access the live conference call by dialing 1-800-894-5910, (US) or 785-424-1052 (International) using the conference ID: 7NEURO. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com. If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-2156 (US) or 402-220-2660 (International) using the conference ID: 7NEURO. The call will be archived for two weeks.

Neurocrine also announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer 20th Annual Healthcare Conference in New York.

The live presentation takes place Tuesday, November 3, 2009 at 11:25 a.m. Eastern Time (ET)/8:25 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):